Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of Verdiperstat for the Treatment of Multiple-System-Atrophy (MSA)

Next Previous
Trial Profile

A Phase III trial of Verdiperstat for the Treatment of Multiple-System-Atrophy (MSA)

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Verdiperstat (Primary)
  • Indications Multiple system atrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company

    • Most Recent Events

    • 23 Jan 2019 According to a Biohaven Pharmaceutical media release, the company expects to initiate this trial in the third quarter of 2019.
    • 02 Dec 2018 New trial record
    • 14 Nov 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company plans to initiate this trial in 2019 for the treatment of MSA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top